دورية أكاديمية
Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
| العنوان: | Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. |
|---|---|
| المؤلفون: | Bolton, Diane L, Pegu, Amarendra, Wang, Keyun, McGinnis, Kathleen, Nason, Martha, Foulds, Kathryn, Letukas, Valerie, Schmidt, Stephen D, Chen, Xuejun, Todd, John Paul, Lifson, Jeffrey D, Rao, Srinivas, Michael, Nelson L, Robb, Merlin L, Mascola, John R, Koup, Richard A |
| المصدر: | J Virol ; ISSN:1098-5514 ; Volume:90 ; Issue:3 |
| بيانات النشر: | Atypon |
| سنة النشر: | 2016 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | Combination antiretroviral therapy (cART) administered shortly after human immunodeficiency virus type 1 (HIV-1) infection can suppress viremia and limit seeding of the viral reservoir, but lifelong treatment is required for the majority of patients. Highly potent broadly neutralizing HIV-1 monoclonal antibodies (MAbs) can reduce plasma viremia when administered during chronic HIV-1 infection, but the therapeutic potential of these antibodies during acute infection is unknown. We tested the ability of HIV-1 envelope glycoprotein-specific broadly neutralizing MAbs to suppress acute simian-human immunodeficiency virus (SHIV) replication in rhesus macaques. Four groups of macaques were infected with SHIV-SF162P3 and received (i) the CD4-binding-site MAb VRC01; (ii) a combination of a more potent clonal relative of VRC01 (VRC07-523) and a V3 glycan-dependent MAb (PGT121); (iii) daily cART, all on day 10, just prior to expected peak plasma viremia; or (iv) no treatment. Daily cART was initiated 11 days after MAb administration and was continued for 13 weeks in all treated animals. Over a period of 11 days after a single administration, MAb treatment significantly reduced peak viremia, accelerated the decay slope, and reduced total viral replication compared to untreated controls. Proviral DNA in lymph node CD4 T cells was also diminished after treatment with the dual MAb. These data demonstrate the virological effect of potent MAbs and support future clinical trials that investigate HIV-1-neutralizing MAbs as adjunctive therapy with cART during acute HIV-1 infection. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1128/JVI.02454-15Test; https://pubmed.ncbi.nlm.nih.gov/26581981Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719604Test/ |
| DOI: | 10.1128/JVI.02454-15 |
| الإتاحة: | https://doi.org/10.1128/JVI.02454-15Test https://pubmed.ncbi.nlm.nih.gov/26581981Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719604Test/ |
| حقوق: | Copyright © 2016, American Society for Microbiology. All Rights Reserved. |
| رقم الانضمام: | edsbas.8EA6345 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1128/JVI.02454-15 |
|---|